First International Conference on New Molecular Targets for Anticancer Therapy, Naples, 22-23 June 1998: Meeting report

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 249-256

  Budillon, Alfredo ^a   Caponigro, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Angiogenesis; Anticancer therapy; Antisense; Cell signaling

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOSTATIC AGENT; GEFITINIB; MIDOSTAURIN; SCH 66366; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; FATIGUE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METASTASIS; NAUSEA; NONHUMAN; PATHOGENESIS; PHARMACOKINETICS; PRIORITY JOURNAL; SAFETY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION; VOMITING;

EID: 0032998284     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00015     Document Type: Conference Paper

References (17)

1. Weiss RB. New source and new antitumor drugs in development. Semin Oncol 1997, 24: 153-5.
2. Huang PS, Heimbrook DC. Oncogene products as therapeutic targets for cancer. Curr Opin Oncol 1997; 9: 94-100.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
4. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-62.
5. Denhardt DT. Signal-transduction protein phosphorylation cascades mediated by ras/rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 1996; 318: 729-47.
6. Aaronson SA, Miki T, Meyers K, Chan A. Growth factors and malignant transformation. Adv Exp Med Biol 1993; 348: 7-22.
7. Levitzki A. Signal trasduction therapy. Eur J Biochem 1994; 226: 1-13.
8. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997; 9: 79-87.
9. Barnes MN, Deshane JS, Siegal GP, et al. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin Cancer Res 1996; 2: 1089-95.
10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rew Oncol/Hematol 1995; 19: 183-232.
11. Tortora G, Ciardiello F, Pepe S, et al. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological-effects in cancer patients. Clin Cancer Res 1995; 1: 377-84
12. Kastan M. Molecular biology of cancer: the cell cycle. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott 1997: 121-34.
13. 1cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
14. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-12.
15. Wagner RW. Gene inhibition using antisense oligodeoxynucleotide. Nature 1994; 372: 332-5.
16. Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997; 76: 151-60.
17. Sikic BI, Yuen AR, Advani R, et al. Antisense oligonucleotide therapy targeted to protein kinase C-alpha (ISIS 3521/CGP64128A) by 21 day infusion: results of the phase I trial and activity in ovarian carcinomas. Proc Am Soc Clin Oncol 1998; 17: 1654a.